Hello everyone!

We hope you and your loved ones are staying safe and healthy through these unusual times🙏. 

Things are advancing a lot; thus, we want to share with you all the progress made this last quarter. Only as a reminder, we have developed a blood-based assay for the early detection of cancer and monitoring of the applied treatments effectiveness, which is enabled by two independent devices created to isolate and analyze circulating tumor cells (CTCs) effectively. These devices are: a processing unit, which efficiently isolates CTCs from blood samples, and an imaging system that automatically counts and analyzes the tumor cells based on their morphology and the expression of specific markers.

Our last update was regarding the development of the commercial versions of the two devices, at that point, most of the work had been done💯. So in this past quarter, we focused on solving all the final details needed to build the commercial versions of these modules. At the moment, we are manufacturing key components to build several units of both modules, estimating that they will be ready for the next quarter update🙌. 

We are proud to present to you how the devices will look like:

In this picture, from left to right, are: the imaging system and the processing unit.  

Furthermore, we have continued the tests with biological samples as a way to corroborate that the processing and imaging systems are working as they should with all the changes that have been made to improve the overall reliability of the assay. So far, the tests indicate that the devices have an excellent performance🔥.

We already have in place a protocol to analyze the captured cells based on their morphology and the expression of specific markers. However, since we wanted to increase the assay capabilities, we are working on a protocol to identify specific molecular markers within the CTCs captured. This will increase the overall sensitivity and specificity of the assay giving it an additional edge.

Also, after having spoken with our Y Combinator and Start X advisors, we decided to run another crowdfunding campaign to secure the funding needed to begin the path to get the FDA clearance to be able to later commercialize our technology as an in vitro diagnostic medical device to hospitals and laboratories. This campaign will be run on Start Engine in the next months, we will let you know the launch date once we have it, hoping that if it is within your means you can support us again🙌.

Finally, we want to thank you again for all the kind words and for the support you have given us, not only during the campaign but throughout this time. Rest assured that we are all giving the extra mile to achieve all the milestones that we set. 

Delee Team 💙